Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

77.60 -2.07 (-2.60%)
Official Closing Price Updated: 4:10 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,886,703
Open 79.78
Bid (Size) 77.75 (10)
Ask (Size) 77.80 (2)
Prev. Close 79.67
Today's Range 77.58 - 79.88
52wk Range 73.31 - 116.26
Shares Outstanding 2,531,374,696
Dividend Yield 4.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre
Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe." 
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Merck & Co's (NYSE: MRK) short interest as a percent of float has risen 16.98% since its last report. According to exchange reported data, there are now 27.71 million shares sold short, which is 1.24%... 
Via Benzinga

Performance

YTD
-21.8%
-21.8%
1 Month
-9.0%
-9.0%
3 Month
-2.6%
-2.6%
6 Month
-11.9%
-11.9%
1 Year
-32.5%
-32.5%

More News

Read More
Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened
Via Stocktwits
Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio
Via Chartmill
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
Via Benzinga
Price Over Earnings Overview: Merck & Co
Via Benzinga
Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda
Via Stocktwits
The Smartest Dividend Stock to Buy With $1,000 Right Now
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
Topics Intellectual Property
3 Dividend Stocks Perfect for Millennial Investors
Via The Motley Fool
Topics Economy Intellectual Property Retirement
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
Via Benzinga
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
Via Benzinga
Topics Government
Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts
Via MarketMinute
Topics Bonds ETFs Economy
FDA Clears Merck's One-Minute Cancer Shot
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff
Via Investor's Business Daily
Topics Intellectual Property
3 Dirt-Cheap Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
Via The Motley Fool
Topics Intellectual Property
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
From Merck & Co., Inc.
Via Business Wire
Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug
Via Benzinga
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
From Merck & Co., Inc.
Via Business Wire
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 77.60
When was Merck & Co last traded?
The last trade of Merck & Co was at 09/25/25 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 196.43B
How many shares of Merck & Co are outstanding?
Merck & Co has 196B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.